Regado Biosciences, Inc., Broadens Patent Family Protecting Core Technology
New Patent Extends Coverage to Peptide- and Protein-Based Control Agents
BASKING RIDGE, N.J., Feb. 12, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Patent and Trademark Office (USPTO) has issued an important patent that expands protection of Regado's core technology platform while broadening the range of aptamer-based therapies upon which Regado may base future products.
Regado's current drug development programs, including its lead REG1 Anticoagulation System, consist of an aptamer-based pharmacologic drug paired with a specific control agent. U.S. patent #8,586,524, the newest issuance in the "Modulators of Pharmacologic Agents" patent family, describes the classes of molecules that can be developed as control agents to modulate aptamer activity in the body. Specifically, '524 extends coverage beyond nucleic acid-based modulators to now include peptide-, polypeptide- and protein-based control agents for the modulation of aptamer-based anticoagulants.
Christopher Rusconi, Ph.D., Regado's chief scientific officer, stated, "Regado is committed to continuously broadening our patent position and leveraging intellectual property to strengthen our novel technology platform. As we continue to advance REG1 through our pivotal Phase 3 REGULATE-PCI trial and closer to potential commercialization, the '524 patent protects Regado from potential competing aptamer-based anticoagulants designed to employ peptide or protein-based modulators. The patent also expands the future development possibilities for anticoagulant products, allowing us to maintain our leadership position in this space, which is critical for attracting potential development partners."
U.S. patent #8,586,524 builds upon U.S. patents #8,283,330 and #7,300,992, which cover a spectrum of oligonucleotide and oligonucleotide-related modulators designed to target anticoagulants specifically ('330), as well as aptamers directed against any other type of molecular target ('992).
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc., is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 study enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.
For more information on REGULATE-PCI, please visit:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein regarding our ability to obtain, maintain, defend and enforce intellectual property rights protecting our product candidates and the scope, coverage and enforceability of our intellectual property rights. Actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from those projected in forward-looking statements include the "Risk Factors" described in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on Nov. 8, 2013, and in the Company's other periodic filings with the SEC.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company has no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contacts:
Tricia Truehart or Chelsea Wheeler
SOURCE Regado Biosciences, Inc.
More by this Source
FDA Designates Regado's REG1 in PCI as a Fast Track Development Program
Mar 10, 2014, 07:30 ET
Regado Biosciences to Provide Year-End and Fourth Quarter 2013 Financial Results
Mar 06, 2014, 07:30 ET
Regado Biosciences to Present at the 26th Annual ROTH Conference
Mar 05, 2014, 07:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.